First-quarter results show revenue growth but higher general and administrative expenses compared to the prior year period.
Coya Therapeutics reported first-quarter GAAP earnings per share of -$0.32 on revenue of $251.1M. The company’s results reflect a loss despite strong revenue performance.
General and administrative expenses rose to $3.8 million for the three months ended March 31, 2026, up $1.1 million from $2.7 million in the same period of 2025. The increase was attributed to operational expansion.
No immediate market reaction was disclosed in the release.